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OPINION
                    
BARRY, Circuit Judge
Plaintiff appeals the dismissal of its consolidated class action securities fraud
complaint – the Second Amended Complaint – which charged Bio-Technology General
Corp. (now Savient Pharmaceuticals, Inc.) and three of its senior officers with making
false and misleading statements about the corporation’s financial performance in 1999,
2000, and 2001.  The District Court dismissed the Second Amended Complaint finding,
       In re Bio-Technology General Corp. Sec. Litig., 380 F.Supp.2d 574 (D.N.J. 2005).  1
       In re Bio-Technology General Corp. Sec. Litig., No. Civ. A. 02-6048, 2006 WL2
3068553 (D.N.J. Oct. 26, 2006).  
3
as it had with reference to the initial consolidated class action complaint, that scienter had
not been adequately pled.  Because plaintiff had already had “two large bites at the apple”
and because further amendment would be futile, the dismissal was with prejudice.  The
predominant issue before us is whether the District Court erred in finding that the Second
Amended Complaint failed to adequately plead scienter.  Our review is plenary.  Winer
Family Trust v. Queen, 503 F.3d 319, 325 (3d Cir. 2007).  
We have reviewed the extensive record in this case; indeed, the complaints alone
cover 120 and 162 pages, respectively.  We have also reviewed the thorough, thoughtful
and, in a word, superb opinions of the District Court, the first opinion comprehensively
analyzing the numerous allegations of the initial consolidated class action complaint in
light of the applicable law and laying out a road map for plaintiff to follow,  and the1
second opinion explaining, after a close review of the Second Amended Complaint, the
deficiencies that remained.   2
This is a case in which we need do no more than recognize the excellence of the
District Court’s opinions; indeed, it would make little or no sense to even attempt to
match the quality of that work.  And so, substantially for the reasons set forth by the
Honorable Harold A. Ackerman, we will affirm.  
